Oligomerix Inc., of New York, said it completed phase I of the scope of work under its Small Business Innovation Research phase I/II fast-track grant to scale up and synthesize a tau oligomer inhibitor to initiate IND-enabling studies in Alzheimer's disease and related dementias. The company recently received $1 million from the NIH's National Institute on Aging to fund phase II activities.